2026-10-13T12:23:19Z https://api.figshare.com/v2/oai

oai:figshare.com:article/33966792 2026-09-22T17:23:57Z category_7 category_19 category_45 category_734 category_106 category_132 portal_5 item_type_3 month_year_09_2026

<p>Total cost per hepatitis C treatment initiation in Georgia, by screening pathway and year of screening, in 2022 USD, and total QALY losses averted by treatments under each screening pathway.</p> Josephine G. Walker (3172986) Irina Tskhomelidze Schumacher (23893026) Shaun Shadaker (7066289) Tamar Gabunia (25091118) Rania A. Tohme (16185542) Akaki Abutidze (4543525) Vladimer Getia (17983647) Peter Vickerman (210007) Medicine Pharmacology Sociology Biological Sciences not elsewhere classified Science Policy Infectious Diseases year time horizon reimbursement records including generic drug costs qaly ), compared decentralized diagnostic testing hospital screening suggest 2018 &# 8211 full daa costs excluding daa costs hepatitis c treatment georgia </ p case finding increased daa costs decreased 2022 usd $) phc potentially cost alternative screening pathways hcv elimination program daa costs alternative screening diagnostic pathways unit costs level costs treatment decreased elimination programs screening pathway xlink "> total number specialized providers primary healthcare primarily due percent linked pay threshold patients screened later stages hrp ), future programs donated direct daas ). care varied calculated patient biggest increase antibody prevalence acting antivirals <p>Total cost per hepatitis C treatment initiation in Georgia, by screening pathway and year of screening, in 2022 USD, and total QALY losses averted by treatments under each screening pathway.</p> 2026-09-22T17:23:48Z Dataset Dataset 10.1371/journal.pgph.0007122.t003 https://figshare.com/articles/dataset/_p_Total_cost_per_hepatitis_C_treatment_initiation_in_Georgia_by_screening_pathway_and_year_of_screening_in_2022_USD_and_total_QALY_losses_averted_by_treatments_under_each_screening_pathway_p_/33966792 CC BY 4.0